Angelman syndrome antisense treatment
MetadataShow full item record
Disclosed herein are antisense oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA at the 5'-end of UBE3A-AS, which is downstream of SNORD115-45 snoRNA. Also disclosed are pharmaceutical compositions and methods for treatment of Angelman syndrome.
Dindot, Scott Victor (12/1). Angelman syndrome antisense treatment. United States. Patent and Trademark Office; Texas A&M University. Libraries. Available electronically from